A Retrospective Analysis of the Impact of Treatments and Blood Counts on Survival and the Risk of Vascular Events During the Course of Polycythemia Vera
Researchers noted concerning survival and vascular complications that hydroxyurea-treated patients with polycythemia vera who needed at least one phlebotomy per year were not significantly different from hydroxyurea-treated patients with a low phlebotomy requirement. Therefore, they concluded that complementary phlebotomy in hydroxyurea-treated patients, in order to maintain hematocrit levels, is safe.
Br J Haematol
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology